Gadolinium-Based Layered Double Hydroxide and Graphene Oxide

Total Page:16

File Type:pdf, Size:1020Kb

Gadolinium-Based Layered Double Hydroxide and Graphene Oxide Usman et al. Chemistry Central Journal (2017) 11:47 DOI 10.1186/s13065-017-0275-3 REVIEW Open Access Gadolinium‑based layered double hydroxide and graphene oxide nano‑carriers for magnetic resonance imaging and drug delivery Muhammad Sani Usman1, Mohd Zobir Hussein1*, Sharida Fakurazi2,3 and Fathinul Fikri Ahmad Saad4 Abstract Gadolinium (Gd)-based contrasts remain one of the most accepted contrast agents for magnetic resonance imaging, which is among the world most recognized noninvasive techniques employed in clinical diagnosis of patients. At ionic state, Gd is considered toxic but less toxic in chelate form. A variety of nano-carriers, including gadolinium oxide ­(Gd2O3) nanoparticles have been used by researchers to improve the T1 and T2 contrasts of MR images. Even more recently, a few researchers have tried to incorporate contrast agents simultaneously with therapeutic agents using single nano-carrier for theranostic applications. The beneft of this concept is to deliver the drugs, such as anticancer drugs and at the same time to observe what happens to the cancerous cells. The delivery of both agents occurs con- currently. In addition, the toxicity of the anticancer drugs as well as the contrast agents will be signifcantly reduced due to the presence of the nano-carriers. The use of graphene oxide (GO) and layered double hydroxides (LDH) as candidates for this purpose is the subject of current research, due to their low toxicity and biocompatibility, which have the capacity to be used in theranostic researches. We review here, some of the key features of LDH and GO for simultaneous drugs and diagnostic agents delivery systems for use in theranostics applications. Keywords: Layered double hydroxides, Graphene oxide, Drug delivery, Gadolinium contrast, Magnetic resonance imaging (MRI) Background Nanotechnology is a promising feld of research, espe- Tere are various modes of cancer therapy, such as chem- cially in the area of the so-called nanomedicine [2–4]. otherapy, immunotherapy and radiotherapy. Notwith- In recent years, 2D inorganic nanolayers such as layered standing, the challenge of successful cancer therapy is double hydroxides, graphene and graphene oxide, and still existing. Chemotherapy is the most accepted method metal nanoparticles-based nano-carriers have been used of cancer therapy amongst the three modes; this is due in various drug delivery applications. Teir advantages to availability of various chemotherapeutic agents. How- are the reduction in toxicity and improvement of ef- ever, the major challenge of this method is the chemo- cacy of chemotherapeutic drugs, which are known to therapeutic agents, which do not target the cancerous be highly toxic to human cells. Lately, eforts have been cells alone but normal cells are also vulnerable to the made by some researchers to simultaneous dope contrast cytotoxic efects of chemotherapeutic agents [1]. agents such as gadolinium ion into the aforesaid nano- carries for theranostic applications [5–9]. Layered double hydroxide (LDH) is a class of inorganic *Correspondence: [email protected] nanolayers [10] and one of the most commonly used 1 Materials Synthesis and Characterization Laboratory, Institute nano-carriers in drug delivery systems. LDH is an inor- of Advanced Technology (ITMA), Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia ganic 2D layered material with interlayer exchangeable Full list of author information is available at the end of the article anions [11], with the general formula, © The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Usman et al. Chemistry Central Journal (2017) 11:47 Page 2 of 10 2+ 3+ + n− ·[ Te slurry obtained is centrifuged/fltered, washed and M1− xMx (OH)2 A x/n mH2O] x oven-dried at 60–80 °C. A variety of anions can be inter- calated between the layers, which lead to the formation of where M2+ and M3+ represent the divalent and trivalent multifunctional nanocomposites [23]. Te ion exchange n− metal cations respectively, and +[A ]x/n represents the technique is much similar to co-precipitation method. interlayer exchangeable anions [11–13]. Te inner layers However, in ion-exchange method, the guest anion solu- also consist of water molecules which assist in uptake of tion is added after the LDH is prepared [22]. As stated molecules [14]. LDH synthesis is usually carried out from earlier, the drug loading capacity of the methods varies precursor solutions of the metal salts under alkali pH based on the nature of the drug or guest anions to be moderator. intercalated. Factors such as hydrothermal treatment, Graphene oxide is a derivative of graphene, a nano- aging process, sonication and microwave assisted syn- material with two dimensions (2D) and an arrangement thesis have been reported to afect the shapes and other of sp2-bonded carbon atoms. It has stupendous proper- physico-chemical properties of the nanocomposites pro- ties such as optical, electronic and thermal stability. GO duced, which in turn infuences the drug loading [24]. is formed when the hydrogen atoms are replaced by oxygen atoms during the chemical synthesis. Te Hum- Application of GO in drug delivery mer’s method is the universally adopted method of GO Te structure of GO consists of sp3-hybridized carbons synthesis from graphite by strong oxidation of the latter which are composed of diferent functional groups, such [15, 16]. Currently, a lot of efort is been put into explora- as hydroxyl, carboxyl, and epoxides. Te groups are con- tion of prospective graphene-based materials in biomedi- nected to the surface of the GO sheets of the sp2 bond- cal applications, such as nano-carriers for drug and gene ing carbon atoms. Tis enables the efcient loading of delivery, biosensing and bioimaging applications [17]. aromatic materials such as anticancer drugs onto the sheets [25]. In similarity with LDH drug delivery sys- Application of LDH in drug delivery tems, GO-based drug delivery system is also a repre- Drug delivery system sentative of a host–guest interactions in supramolecular Drug delivery system refers to the typically the use of chemistry, where the host and the guest molecules or ions nano-carriers as host to accommodate or load therapeutic are bonded non-covalently mostly via hydrogen bonds, agents as guest for delivery to specifc targets. LDH is one ionic bonds, van der Waals interactions and hydropho- of the most commonly used drug delivery agents. LDH bic bonds [26]. In addition, GO contains a stupendous π has a 2D-layered structure which gives it a unique abil- structure that enables noncovalent π–π stacking bond- ity to intercalate and exchange anions with other materi- ing with loaded therapeutics [27]. Due to its composi- als, which enables it to be used as a drug carrier [18–20]. tion, GO is equally capable of OH and COOH hydrogen Another interesting property of LDH is its pH-dependent bonding, hydrophobic bonding, embedding and surface controlled release properties. Tis specifcally makes its absorption [28] with functional groups of various drugs resourceful in pharmaceutical applications. Te synthesis [28]. Tis facilitates drug to GO bonding for the forma- of LDH can be conducted via two major chemical routes, tion of the nanocomposite and eventually release of the which are co-precipitation or ion-exchange method; both drug in the desired pH [29]. methods can be utilized for drug intercalation and have As mentioned earlier, the most commonly used meth- been reported to have high drug loading capacities [21]. ods of GO synthesis are Hummers’ and Hummers’ Nevertheless, some reports indicate diferent percentage modifed methods [30], which are top-down chemi- loading for the methods under the same conditions [22], cal approach of synthesizing GO from graphite fakes. which may be due to the nature of the therapeutic agents. Briefy, graphite fakes and sodium nitrate are frstly Co-precipitation is the most adopted technique for LDH mixed and concentrated sulphuric acid is then added synthesis, due to its drug loading ability and is often under constant stirring and allowed to stir for about an considered as the easiest method. In co-precipitation hour. Appropriate amount of KMnO 4 is slowly added method, an aqueous precursor solution of two diferent to the solution at low temperature. Te solution is metal salts is prepared; to which an anionic guest and then allowed to stir further for 12 h at a temperature of alkaline solution are simultaneously added in drop wise 35–50 °C. Te solution is then diluted with 500 mL of manner. Te set-up is then kept under stirring at room deionized water. Treatment with 30% H 2O2 is followed. temperature with continuous hydrogen fush until a pH Te fnal suspension is then washed with HCl and H2O, between 7 and 10 is attained. Te mixed solution is then fltered and dried at low temperature. GO synthesis is put through aging process for 18 h at 70 °C temperature. conducted with caution to prevent explosion [31]. Usman et al. Chemistry Central Journal (2017) 11:47 Page 3 of 10 Gadolinium‑based nanodelivery system for MR referred to as theranostic drug delivery system (Fig. 1a, imaging and drug delivery b). However, when only a diagnostic agent is loaded on a Magnetic resonance imaging (MRI) is a powerful and nano-carrier, it becomes a diagnostic delivery system [40]. one of the most commonly used clinical approaches Recently, researches have been focused on doping MRI in diagnosis of cancer patients [32].
Recommended publications
  • ++449Guide to Radiology Procedures.Pdf
    For Alexander and Olivia For Elsevier Content Strategist: Jeremy Bowes Content Development Specialist: Helen Leng Project Manager: Julie Taylor Designer/Design Direction: Miles Hitchen Illustration Manager: Jennifer Rose Illustrator: David Gardner and Antbits Ltd CHAPMAN AND NAKIELNY’S GUIDE TO RADIOLOGICAL PROCEDURES Edited by Nick Watson MBChB MRCP FRCR Consultant Radiologist, University Hospital of North Staffordshire, Stoke-on-Trent; Senior Lecturer, Keele University Medical School, Keele, UK SIXTH EDITION Edinburgh • London • New York • Oxford • Philadelphia • St Louis • Sydney • Toronto 2014 © 2014 Elsevier Ltd. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions. This book and the individual contributions contained in it are protected under copyright by the publisher (other than as may be noted herein). First edition 1981 Second edition 1986 Third edition 1993 Fourth edition 2001 Fifth edition 2009 Sixth edition 2014 ISBN 9780702051814 Ebook ISBN: 9780702054792 British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Library of Congress Cataloging in Publication Data A catalog record for this book is available from the Library of Congress Notices Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • Magnetic Resonance Imaging (MRI) Contrast Agents Frequently Asked Questions
    Magnetic Resonance Imaging (MRI) Contrast Agents Frequently Asked Questions 1. What is an MRI contrast agent? MRI contrast agents are chemical substances that contain the metal gadolinium. They are injected through a vein for many magnetic resonance imaging (MRI) scans. 2. What are the benefits of MRI contrast agents? When injected through a vein into the body, MRI contrast agents improve how internal organs, blood vessels, and other tissues look on the MRI images. This helps detect problems and diagnose medical conditions. For many medical conditions, the use of MRI contrast agents is a necessary part of the MRI. 3. What are the risks from MRI contrast agents? A. Injection problems. Any injection can cause injury to a nerve, artery, or vein, or result in infection. The contrast agent can also sometimes leak outside of the vein into the soft tissues during injection. This is called extravasation and is uncommon (about 1 in every 1,000 injections). This may be painful, but the pain is generally relieved by cold or warm compresses. B. Allergic reaction. Some people can be allergic to MRI contrast agents. There can sometimes be a mild reaction to the contrast agent such as itching and hives (about 1 in every 100 injections). Uncommonly, there can be a serious reaction to the contrast agent such as changes in blood pressure, cardiac distress, and respiratory distress (about 1 in every 10,000 injections). Very rarely this can result in death. For patients who have had a previous mild allergic reaction to an MRI contrast agent and need another MRI with MRI contrast agent, it is generally safe to do so after taking anti-allergy medications.
    [Show full text]
  • 207/2015 3 Lääkeluettelon Aineet, Liite 1. Ämnena I Läkemedelsförteckningen, Bilaga 1
    207/2015 3 LÄÄKELUETTELON AINEET, LIITE 1. ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN, BILAGA 1. Latinankielinen nimi, Suomenkielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Latinskt namn Finskt namn Svenskt namn Engelskt namn (N)-Hydroxy- (N)-Hydroksietyyli- (N)-Hydroxietyl- (N)-Hydroxyethyl- aethylprometazinum prometatsiini prometazin promethazine 2,4-Dichlorbenzyl- 2,4-Diklooribentsyyli- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcoholum alkoholi alcohol 2-Isopropoxyphenyl-N- 2-Isopropoksifenyyli-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- methylcarbamas metyylikarbamaatti metylkarbamat methylcarbamate 4-Dimethyl- ami- 4-Dimetyyliaminofenoli 4-Dimetylaminofenol 4-Dimethylaminophenol nophenolum Abacavirum Abakaviiri Abakavir Abacavir Abarelixum Abareliksi Abarelix Abarelix Abataceptum Abatasepti Abatacept Abatacept Abciximabum Absiksimabi Absiximab Abciximab Abirateronum Abirateroni Abirateron Abiraterone Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoni natrium Acediasulfon natrium Acediasulfone sodium Acenocoumarolum Asenokumaroli Acenokumarol Acenocumarol Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • Physician Services Fee Schedule
    REPORT: RS04328‐R1328 NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES PHYSICIAN FEE SCHEDULE AS OF: 05/11/2017 Physician Fee Schedule Provider Specialty 001 Effective Date: 1/1/2018 The inclusion of a rate on this table does not guarantee that a service is covered. Please refer to the Medicaid Billing Guide and the Medicaid and Health Choice Clinical Policies on the DMA Web Site. Providers should always bill their usual and customary charges. Please use the monthly NC Medicaid Bulletins for additions, changes and deletion to this schedule. Medicaid Maximum Allowable NON- FACILITY FACILITY PROCEDURE CODE MODIFIER PROCEDURE DESCRIPTION RATE RATE EFFECTIVE DATE 01967 NEURAXIAL LABOR ANALGESIA/ANESTHESIA FOR $ 209.63 $ 209.63 01996 DAILY HOSPITAL MANAGEMENT OF EPIDURAL OR $ 38.93 $ 38.93 10021 FINE NEEDLE ASPIRATION; WITHOUT IMAGING $ 52.36 $ 100.48 10022 FINE NEEDLE ASPIRATION; WITH IMAGING GUI $ 51.97 $ 103.17 10030 GUIDE CATHET FLUID DRAINAGE $ 126.07 $ 615.23 10035 PERQ DEV SOFT TISS 1ST IMAG $ 74.46 $ 437.80 10036 PERQ DEV SOFT TISS ADD IMAG $ 37.49 $ 379.35 10040 ACNE SURGERY $ 63.53 $ 72.20 10060 DRAINAGE OF ABSCESS $ 67.39 $ 77.74 10061 DRAINAGE OF ABSCESS $ 120.14 $ 133.85 10080 DRAINAGE OF PILONIDAL CYST $ 68.87 $ 114.75 10081 DRAINAGE OF PILONIDAL CYST $ 120.71 $ 181.14 10120 FOREIGN BODY REMOVAL, SKIN $ 66.08 $ 94.90 10121 FOREIGN BODY REMOVAL, SKIN $ 135.29 $ 185.09 10140 DRAINAGE OF BLOOD EFFUSION $ 86.33 $ 109.27 10160 PUNCTURE DRAINAGE OF LESION $ 69.52 $ 88.81 10180 INCISION AND DRAINAGE, COMPLEX $ 127.40 $ 164.05
    [Show full text]
  • Sonovue® – Liver Dynamic Contrast Enhancement in Real Time
    Bracco. The contrast imaging specialists. SonoVue® – Liver Dynamic Contrast Enhancement in Real Time BRACCO IMAGING Welcome to Bracco Imaging Bracco Imaging S.p.A., part of the Bracco Group, is one of the world’s leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs. Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-Ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), Nuclear Medicine through radioactive tracers, and Gastrointestinal Endoscopy. The diagnostic imaging offer is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of radiology and cardiology. These include the Empower line of contrast injection systems for CT and MRI procedures, the syringe-less contrast administration system CT Exprés and VueJect, our ultrasound contrast agents’ infusion pump. The Company operates in over 90 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. With an on-going research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America; Europe and Japan operating through the Joint Venture Bracco-Eisai Co., Ltd. The Company also operates in Brazil, South Korea, and China through the Joint Venture Bracco Sine Pharmaceutical Corp. Ltd. Operational investments have been made in order to achieve top quality and compliance with a sustainable eco-friendly production. Manufacturing activities are located in Italy, Switzerland, Japan, China and Germany.
    [Show full text]
  • Gadolinium Based Contrast Agents
    CE Credits Available CONSIDERATIONS IN THE SELECTION OF A NEW GADOLINIUM-BASED CONTRAST AGENT SUPPLEMENT TO MAY 2014 THE JOURNAL OF PRACTICAL MEDICAL IMAGING AND MANAGEMENT Considerations in the Selection of a New Gadolinium-Based Contrast Agent Michael F. Tweedle, PhD Emanuel Kanal, MD, FACR, FISMRM Robert Muller, PhD Stefanie Spielman Professor of Radiology Professor of Radiology and Neuroradiology Department of General, Organic & The Ohio State University University of Pittsburgh Medical Center Biochemical Chemistry Columbus, OH Pittsburgh, PA University of Mons Mons, Belgium Supported by an unrestricted educational grant from © May 2014 www.appliedradiology.com SUPPLEMENT TO APPLIED RADIOLOGY n 1 Publisher Kieran Anderson Executive Editor Cristen Bolan Art and Production Barbara A. Shopiro Applied Radiology and this supplement, Considerations in the Selection of a New Gadolinium-Based Contrast Agent, are published by Anderson Publishing, Ltd. The journal does not warrant the expertise of any author in a particular field, nor is it responsible for any statements by such authors. The opinions expressed in this supplement are those of the authors. They do not imply endorsement of advertised products and do not necessarily reflect the opinions or recommendations of our sponsors or the editors and staff of Applied Radiology. Copyright © 2014 by Anderson Publishing, Ltd., 180 Glenside Avenue, Scotch Plains, NJ 07076 All rights reserved. Cover images courtesy of Howard A. Rowley, MD. Considerations in the Selection of a New Gadolinium-Based Contrast Agent Our 3 esteemed faculty summarize the similarities and differences among the gadolinium-based contrast agents (GBCAs) currently utilized for magnetic resonance imaging (MRI), with emphasis on stability and relaxivity.
    [Show full text]
  • DISSERTATION INVESTIGATION of CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY for the EVALUATION of EQUINE ARTICULAR CARTILAGE Su
    DISSERTATION INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Submitted by Bradley B. Nelson Department of Clinical Sciences In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Fall 2017 Doctoral Committee: Advisor: Christopher E. Kawcak Co-Advisor: Laurie R. Goodrich C. Wayne McIlwraith Mark W. Grinstaff Myra F. Barrett Copyright by Bradley Bernard Nelson 2017 All Rights Reserved ABSTRACT INVESTIGATION OF CATIONIC CONTRAST-ENHANCED COMPUTED TOMOGRAPHY FOR THE EVALUATION OF EQUINE ARTICULAR CARTILAGE Osteoarthritis and articular cartilage injury are substantial problems in horses causing joint pain, lameness and decreased athleticism resonant of the afflictions that occur in humans. This debilitating joint disease causes progressive articular cartilage degeneration and coupled with a poor capacity to heal necessitates that articular cartilage injury is detected early before irreparable damage ensues. The use of diagnostic imaging is critical to identify and characterize articular cartilage injury, though currently available methods are unable to identify these early degenerative changes. Cationic contrast-enhanced computed tomography (CECT) uses a cationic contrast media (CA4+) to detect the early molecular changes that occur in the extracellular matrix. Glycosaminoglycans (GAGs) within the extracellular matrix are important for the providing the compressive stiffness of articular cartilage and their degradation is an early event in the development of osteoarthritis. Cationic CECT imaging capitalizes on the electrostatic attraction between CA4+ and GAGs; exposing the proportional relationship between the amount of GAGs present within and the amount of CA4+ that diffuses into the tissue. The amount of CA4+ that resides in the tissue is then quantified through CECT imaging and estimates tissue integrity through nondestructive assessment.
    [Show full text]
  • Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017
    Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017 DOTAREM® (gadoterate meglumine) Injection NDA 204781 Guerbet LLC, 821 Alexander Rd, Princeton, NJ 08540 OPTIMARK® (gadoversetamide) Injection NDAs 020937, 020975 & 020976 Liebel-Flarsheim Company LLC, 1034 Brentwood Blvd., Richmond Heights, MO 63117 ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Information provided within this briefing document is based upon medical and scientific information available to date. ADVISORY COMMITTEE BRIEFING MATERIALS AVAILABLE FOR PUBLIC RELEASE Page 1 / 168 Dotarem® (gadoterate meglumine) Injection – NDA# 204781 Advisory Committee Optimark® (gadoversetamide) Injection - NDAs# 020937, 020975 & 020976 Briefing Document EXECUTIVE SUMMARY Gadolinium-based contrast agents (GdCAs) are essential for use in magnetic resonance imaging (MRI). Although non-contrast-enhanced MRI may be sufficient for use in some clinical conditions, contrast-enhanced MRI (CE-MRI) using GdCA provides additional vital diagnostic information in a number of diseases. It is widely recognized that CE-MRI increases diagnostic accuracy and confidence, and thus can impact the medical and/or surgical management of patients. Based on the chemical structure of the complexing ligand, GdCA are classified as linear (L-GdCA) or macrocyclic (M-GdCA) and can be ionic or nonionic and those characteristics have a dramatic influence on the stability of the GdCA. Dotarem®, a M-GdCA, was first approved in France in 1989. US-FDA approval was obtained in March 2013 for “intravenous use with MRI of the brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity”, at the dose of 0.1 mmol/kg BW.
    [Show full text]
  • PRESCRIBING INFORMATION CLARISCAN™ – Gadoteric Acid Please Refer to Full National Summary of Product Characteristics (Smpc) Before Prescribing
    PRESCRIBING INFORMATION CLARISCAN™ – gadoteric acid Please refer to full national Summary of Product Characteristics (SmPC) before prescribing. Further information available on request. PRESENTATION Clariscan 0.5 mmol/mL solution for injection. Solution for injection containing 279.3 mg/ml gadoteric acid (as gadoterate meglumine) equivalent to 0.5 mmol/mL. INDICATIONS For diagnostic use only. Clariscan should be used only when diagnostic information is essential and not available with unenhanced magnetic resonance imaging (MRI). Contrast agent for contrast enhancement in MRI for a better visualisation/delineation. Adult and paediatric population (0-18 years): lesions of the brain, spine, and surrounding tissues. Adults and children over 6 months Whole body MRI. Non-coronary angiography in adults only. DOSAGE AND METHOD OF ADMINISTRATION This medicinal product should only be administered by trained healthcare professionals with technical expertise in performing and interpreting gadolinium enhanced MRI. The lowest dose that provides sufficient enhancement for diagnostic purposes should be used. The dose should be calculated based on the patient’s body weight, and should not exceed the recommended dose per kilogram of body weight detailed in this section. MRI of brain and spine: Adults: The recommended dose is 0.1 mmol/kg BW, i.e. 0.2 mL/kg BW. In patients with brain tumours, an additional dose of 0.2 mmol/kg BW, i.e. 0.4 mL/kg BW, may improve tumor characterisation and facilitate therapeutic decision making. Children (0-18 years): The recommended and maximum dose of Clariscan is 0.1 mmol/kg body weight. Do not use more than one dose during a scan.
    [Show full text]